Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Last Updated: August 19, 2022

Investigational Drug Information for ENMD-1198

✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions

What is the development status for investigational drug ENMD-1198?

ENMD-1198 is an investigational drug.

There have been 8 clinical trials for ENMD-1198. The most recent clinical trial was a Phase 2 trial, which was initiated on April 1^st 2010.

The most common disease conditions in clinical trials are Carcinoma, Neoplasms, and Breast Neoplasms. The leading clinical trial sponsors are CASI Pharmaceuticals, Inc., University Health Network, Toronto, and Indiana University Melvin and Bren Simon Cancer Center.

Summary for ENMD-1198

US Patents	0
International Patents	0
US Patent Applications	56
WIPO Patent Applications	27
Japanese Patent Applications	33
Clinical Trial Progress	Phase 2 (2010-04-01)
Vendors	13

Recent Clinical Trials for ENMD-1198

Title	Sponsor	Phase
A Multi-center, Open-label Study of Oral ENMD-2076 for the Treatment of Patients With Advanced Fibrolamellar Carcinoma	CASI Pharmaceuticals, Inc.	Phase 2
A Study of ENMD-2076 in Ovarian Clear Cell Cancers	University Health Network, Toronto	Phase 2
Study of ENMD-2076 in Patients With Advanced/Metastatic Soft Tissue Sarcoma	University Health Network, Toronto	Phase 2

See all ENMD-1198 clinical trials

Clinical Trial Summary for ENMD-1198

Top disease conditions for ENMD-1198

Top clinical trial sponsors for ENMD-1198

See all ENMD-1198 clinical trials

US Patents for ENMD-1198

+ Get email alerts for changes to this table

Subscribe to access the full database, or Try it Free
Drugname	Patent Number	Patent Title	Patent Assignee	Estimated Expiration
>Drugname	>Patent Number	>Patent Title	>Patent Assignee	>Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts

AstraZeneca

Moodys

Mallinckrodt

Harvard Business School

Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.